Clinical Trial

α-N-acetylgalactosaminidase in Methamphetamine Psychosis

Completed
View on ClinicalTrials.gov →
Summary
This cross-sectional observational cohort study examined serum α-N-acetylgalactosaminidase levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study aimed to determine whether decreased α-N-acetylgalactosaminidase levels are associated with psychotic symptoms in methamphetamine users.
Trial Details
NCT Number NCT07434401
Lead Sponsor Elazığ Mental Health and Diseases Hospital
Conditions Methamphetamine Use Disorder, Methamphetamine-induced Psychosis
Enrollment 93 participants
Start Date 2025-05-01
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-25